Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer

Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer

BACKGROUND: Abiraterone acetate is an effective drug for castration-resistant prostate cancer, but cardiac serious adverse events (SAEs) may occur. We studied their association with N-terminal pro–brain natriuretic peptide (NT-proBNP) and troponin T (TnT) during abiraterone therapy. PATIENTS AND MET...

Full description

Bibliographic Details
Main Authors:	Sara Campora, Eleonora Campazzi, Silvia Zanardi, Matteo Puntoni, Marco Piccininno, Arnoldo Piccardo, Mehrdad Shoushtari Zadeh Naseri, Carlotta Defferrari, Nicoletta Provinciali, Marilena Petrera, Domenico Marra, Ennio Biscaldi, Gian Carlo Antonucci, Damiano Ricci, Matteo Clavarezza, Alessandra Gennari, Alberto Gozza, Mauro D'Amico, Marco Mori, Andrea DeCensi
Format:	Article
Language:	English
Published:	Elsevier 2016-12-01
Series:	Translational Oncology
Online Access:	http://www.sciencedirect.com/science/article/pii/S1936523316300365

Similar Items

A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer
by: Carlotta Defferrari, et al.
Published: (2012-06-01)

Durable complete remission after Pembrolizumab in pretreated advanced endometrial cancer: A case report
by: Nicoletta Provinciali, et al.
Published: (2022-09-01)

The nurse-physician collaboration: a survey among Internal Medical Units in Liguria region
by: Roberta Rapetti, et al.
Published: (2014-12-01)

Serum Biomarkers to Dynamically Predict the Risk of Cardiovascular Events in Patients under Oncologic Therapy. A Multicenter Observational Study
by: Nicoletta Provinciali, et al.
Published: (2024-07-01)

The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients
by: Marilena Petrera, et al.
Published: (2018-12-01)

Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art
by: Nicoletta Provinciali, et al.
Published: (2022-12-01)

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
by: Edgar Linden-Castro, et al.
Published: (2014-01-01)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
by: Mostaghel EA
Published: (2014-01-01)

To Enhance or Not to Enhance? The Role of Contrast Medium <sup>18</sup>F-FDG PET/CT in Recurrent Ovarian Carcinomas
by: Michela Massollo, et al.
Published: (2021-06-01)

To switch or not to switch? A real-life experience using dexamethasone in combination with abiraterone
by: Elisa Zanardi, et al.
Published: (2019-06-01)

Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy
by: Benjamin A. Gartrell, et al.
Published: (2015-08-01)

Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
by: Zobniw CM, et al.
Published: (2014-08-01)

Concomitant antihypertensive medication and outcome of patients with metastatic castration‐resistant prostate cancer receiving enzalutamide or abiraterone acetate
by: Ondřej Fiala, et al.
Published: (2024-01-01)

Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer
by: Yutaka Yamamoto, et al.
Published: (2018-01-01)

The first experience in using abiraterone acetate in patients with castration-refractory prostate cancer
by: L. M. Rapoport, et al.
Published: (2015-11-01)

PSA flare in metastatic castration-resistant prostate cancer patients treated with abiraterone or docetaxel
by: Hui-Ying Liu, et al.
Published: (2016-06-01)

The Role of CENPK Splice Variant in Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer
by: Minhong Huang, et al.
Published: (2024-09-01)

The association of AR-V7 with resistance to Abiraterone in metastatic castration-resistant prostate cancer
by: Shuo Wang, et al.
Published: (2022-03-01)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
by: Giuseppe Fallara, et al.
Published: (2023-06-01)

Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics
by: Atefeh Deris, et al.
Published: (2023-01-01)

Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics.
by: Atefeh Deris, et al.
Published: (2023-01-01)

A Study on the Clinical Outcome of Abiraterone Acetate in Castration Resistant Prostate Cancer Patients
by: Aloysius James, et al.
Published: (2018-01-01)

Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer
by: Stefanie Fischer, et al.
Published: (2020-01-01)

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
by: Rosenberg JE, et al.
Published: (2012-01-01)

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
by: Gustavo Werutsky, et al.
Published: (2019-05-01)

Prognostic factors for patients treated with abiraterone
by: Cecília M Alvim, et al.
Published: (2020-02-01)

SPECTROPHOTOMETRIC AND LUMINESCENCE DETERMINATION OF ABIRATERONE ACETATE
by: I. I. Leonenko, et al.
Published: (2015-02-01)

Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis
by: Giovanni Farinea, et al.
Published: (2024-08-01)

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer
by: Masaru Tani, et al.
Published: (2023-09-01)

An experience with abiraterone as treatment for metastatic castration-resistant prostate cancer: Changhua christian hospital experience
by: Wan-yun Fang, et al.
Published: (2016-06-01)

Osteoblast Secretome Modulated by Abiraterone Treatment Affects Castration Resistant Prostate Cancer Cell Proliferation
by: Michele Iuliani, et al.
Published: (2022-09-01)

Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation
by: Simon Rauch, et al.
Published: (2016-06-01)

Influence of treatment with abiraterone and enzalutamide on development of sarcopenia in patients with metastatic castration resistant prostate cancer
by: S. Fischer, et al.
Published: (2020-07-01)

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
by: Yoshinori Yanai, et al.
Published: (2019-07-01)

Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
by: Mamta Parikh, et al.
Published: (2021-03-01)

Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
by: Ayşe Demirci, et al.
Published: (2021-07-01)

Exploring the Prognostic and Predictive Roles of Ki-67 in Endometrial Cancer
by: Laura Paleari, et al.
Published: (2023-11-01)

Usage, effectiveness and safety of abiraterone in prostate cancer
by: J. M. Caro Teller, et al.
Published: (2014-03-01)

Quadriplegia secondary to abiraterone-induced severe hypokalemia
by: Jignesh B Rajvanshi, et al.
Published: (2019-01-01)

Abiraterone Acetate Withdrawal Syndrome: Does It Exist
by: Hélène Gauthier, et al.
Published: (2012-07-01)